Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

@article{Bouch2004RandomizedMP,
  title={Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.},
  author={Olivier Bouch{\'e} and Jean Luc Raoul and Franck Bonnetain and M. Andrea Giovannini and Pierre Luc Etienne and G{\'e}rard Lledo and Dominique Ars{\`e}ne and Jean Francois Paitel and V{\'e}ronique Gu{\'e}rin-Meyer and Emmanuel Mitry and Bruno Buecher and Marie Christine Kaminsky and Jean François Seitz and Philippe Rougier and Laurent Bedenne and Christelle Milan},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 21},
  pages={
          4319-28
        }
}
PURPOSE To determine the efficacy and safety of a biweekly regimen of leucovorin (LV) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study. PATIENTS AND METHODS One hundred thirty-six patients (two were ineligible) were enrolled onto the randomized multicenter phase II trial. Patients received LV 200 mg/m(2) (2-hour infusion) followed by FU 400 mg/m(2… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 103 CITATIONS

FILTER CITATIONS BY YEAR

2005
2018

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 5 Citations per year over the last 3 years

Similar Papers

Loading similar papers…